Clinical Significance of Liquid Biopsy in Brain Tumor Patients: a 5-ALA Guided Approach
Glioblastoma (GBM) is the most common and lethal primary brain tumor. Identifying blood biomarkers that reflect the tumor's status is a major unmet need for optimal clinical management. 5-ALA (5-Aminolevulinic Acid) administration leads to the accumulation of fluorescent Protoporphyrin IX (PpIX) in GBM cells, allowing identification during surgery. This project aims to leverage 5-ALA induced fluorescence to maximize the informational power of plasma liquid biopsy as a tool for diagnosis, post-treatment follow-up, and as a prognostic tool in patients with GBM.
• Inclusion Criteria (Glioblastoma Patients):
• Patient aged 18 years or older
• Diagnosis of supratentorial glioblastoma at its first occurrence (Grade 4, WHO 2021), confirmed through histological analysis, in a brain area that is accessible for surgical removal.
• Ability of the patient to give informed consent.
• Suitability for surgery with fluorescence guidance using 5-ALA.
• Patient aged 18 years or older
• Ability of the patient to give informed consent.
• Suitability for surgery with fluorescence guidance using 5-ALA.